Virus cocktail aims to make inoperable esophageal cancer removable

NCT ID NCT07061704

Recruiting now Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether injecting a cancer-killing virus directly into tumors, combined with standard chemotherapy and an immunotherapy drug, can shrink advanced esophageal cancer enough to allow surgery. About 40 adults with unresectable locally advanced esophageal squamous cell carcinoma will receive the virus every 3 weeks along with intravenous chemo and immunotherapy. The goal is to see if this approach can turn inoperable tumors into operable ones and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oncolytic virus (injected into tumors) plus chemotherapy and an immune checkpoint inhibitor
What this could lead to: If successful, this combination could shrink inoperable esophageal tumors enough to allow surgery, potentially improving survival and quality of life.
What could go wrong: This is an early-phase, single-arm trial with only 40 participants, so results may not apply broadly. The virus injection carries risks like infection or inflammation, and the combination may cause severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.